ValuEngine upgraded shares of Cancer Genetics (NASDAQ:CGIX) from a strong sell rating to a sell rating in a research note issued to investors on Friday.

A number of other research firms also recently issued reports on CGIX. Zacks Investment Research upgraded Cancer Genetics from a sell rating to a hold rating in a report on Wednesday, November 29th. HC Wainwright set a $6.00 price objective on Cancer Genetics and gave the stock a buy rating in a report on Wednesday, November 29th. Finally, Maxim Group began coverage on Cancer Genetics in a report on Thursday, December 7th. They issued a buy rating and a $6.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $5.56.

Cancer Genetics (CGIX) opened at $1.90 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.01 and a current ratio of 2.01. The company has a market capitalization of $51.25, a P/E ratio of -1.96 and a beta of 1.14. Cancer Genetics has a twelve month low of $1.75 and a twelve month high of $5.30.

Cancer Genetics (NASDAQ:CGIX) last announced its earnings results on Thursday, November 9th. The medical research company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Cancer Genetics had a negative net margin of 54.65% and a negative return on equity of 46.21%. research analysts expect that Cancer Genetics will post -0.82 EPS for the current year.

In other news, Director John Pappajohn acquired 150,000 shares of the firm’s stock in a transaction on Friday, December 8th. The stock was acquired at an average price of $1.86 per share, for a total transaction of $279,000.00. Following the completion of the acquisition, the director now owns 2,781,204 shares in the company, valued at $5,173,039.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 21.30% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CGIX. Northern Trust Corp grew its stake in shares of Cancer Genetics by 61.0% in the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after acquiring an additional 12,168 shares during the last quarter. Granahan Investment Management Inc. MA grew its stake in shares of Cancer Genetics by 26.3% in the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock worth $641,000 after acquiring an additional 49,371 shares during the last quarter. Perkins Capital Management Inc. grew its stake in shares of Cancer Genetics by 22.7% in the fourth quarter. Perkins Capital Management Inc. now owns 989,700 shares of the medical research company’s stock worth $1,831,000 after acquiring an additional 183,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Cancer Genetics by 61.9% in the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after acquiring an additional 197,619 shares during the last quarter. 11.08% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Cancer Genetics (CGIX) Raised to “Sell” at ValuEngine” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/cancer-genetics-cgix-raised-to-sell-at-valuengine/1841833.html.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.